Company Analysis
Sign in

Annexon, Inc. (ANNX)

Nasdaq: ANNX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.6
◀ Past 5.2● Present 5.6▶ Future 5.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Report filedMar 30, 2026Mar 3, 2025Mar 26, 2024Mar 6, 2023Mar 1, 2022Mar 25, 2021·
Research and development184,698119,448113,756112,501100,06649,27124,524
General and administrative31,70934,62529,96733,09830,64714,1987,994
Total operating expenses216,407154,073143,723145,599130,71363,46932,518
Operating income-216,407-154,073-143,723-145,599-130,713-63,469-32,518
Other income (expense), net·····571,009
Income before income taxes-206,690-138,200r134,237141,947130,323r-63,412-37,179
Income tax expense0000··4
Net income-206,690-138,200-134,237-141,947-130,323-63,412-37,183
Net income to common shareholders-208,547-138,200·-141,947-130,323-70,336-38,278
Earnings per share, basic-1.34-1.01-1.77-2.60-3.40··
Earnings per share, diluted-1.34-1.01-1.77-2.60-3.40··
Earnings per share, basic and diluted····-3.40-4.15-88.30
Weighted average shares, basic155,105,832137,404,14575,673,08154,673,57238,316,273··
Weighted average shares, diluted155,105,832137,404,14575,673,08154,673,57238,316,273··
Weighted average shares, basic and diluted····38,316,27316,962,398433,493
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton ANNX · research, not advice